Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

Cardiovascular adverse events (CVAEs) are linked to Carfilzomib (CFZ) therapy in multiple myeloma (MM); however, no validated protocols on cardiovascular risk assessment are available. In this prospective study, the effectiveness of the European Myeloma Network protocol (EMN) in cardiovascular risk...

Full description

Bibliographic Details
Main Authors: Anna Astarita, Giulia Mingrone, Lorenzo Airale, Fabrizio Vallelonga, Michele Covella, Cinzia Catarinella, Marco Cesareo, Giulia Bruno, Dario Leone, Carlo Giordana, Giusy Cetani, Marco Salvini, Francesca Gay, Sara Bringhen, Franco Rabbia, Franco Veglio, Alberto Milan
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
multiple myeloma
carfilzomib
cardiovascular adverse events
cardiovascular risk assessment
arterial hypertension
echocardiography
Online Access:https://www.mdpi.com/2072-6694/13/7/1631

Internet

https://www.mdpi.com/2072-6694/13/7/1631

Similar Items